An international consortium of groups from Canada, the United States and the United Kingdom have come together to create an innovative, cloud-based, public challenge running on the Google Cloud Platform to optimize the discovery of genetically distinct groups of cells within cancers that could respond differently to treatment and have different risk of spreading. The ICGC-TCGA DREAM Somatic Mutation Calling Heterogeneity (SMC-Het) Challenge is the first project in the world to marry crowd-sourced benchmarking and cloud-based execution of DNA sequencing analysis pipelines to improve our understanding of tumour DNA. The Challenge launched on November 16, 2015 and will run until May 2016. Sign up to participate at: https://www.synapse.org/SMCHet.
ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced that the Company has entered into a non-exclusive licensing agreement with Takara Bio, Inc. Takara will utilize certain portions of ViaCyte’s cell differentiation technology to expand its stem cell product line, marketed under the Cellartis® brand. Takara will make the technology available for research purposes only, not for clinical or commercial application.
An Innovative Sample Management Partnership with the Crohn’s & Colitis Foundation is Advancing Precision Medicine Through Novel Research to Find a Cure for IBD
As the global leader in comprehensive sample management solutions, BioStorage Technologies has entered into a strategic partnership with the (CCFA) to provide innovative sample management and transformative technology services across the entire sample lifecycle including logistics, kitting, bioprocessing, storage and distribution of samples for its new IBD Plexus initiative.
The Icahn School of Medicine at Mount Sinai Uses Ayasdi for Data Analysis to Identify Subtypes of Diabetes in an Advance for Precision Medicine
Ayasdi today announced the publication of a major new finding on the sub-typing of type 2 diabetes by long-time collaborator, the Icahn School of Medicine at Mount Sinai. The findings, published in the prestigious Science journal, Science Translational Medicine, demonstrates that with the right data, technologies and researchers, precision medicine can become a reality.
Children’s Cancer Institute Selects Labmatrix to Enhance their Research into Curing Childhood Cancers
BioFortis today announced that Children’s Cancer Institute has licensed Labmatrix®, the award-winning precision medicine and biobanking software platform, to support their “Zero Childhood Cancer” program. Labmatrix connects data collected in clinical studies to data discovered in research laboratories, creating a richly-annotated research platform including a full-featured biobanking capability. The connections between patient treatment, diagnostic testing results and drug development are vital for precision medicine. Labmatrix software includes its integrated query tool, Qiagram®, which allows researchers to analyze and refine their data, helping Children’s Cancer Institute to transform their discoveries into new treatments quickly and efficiently.